In conclusion, we demonstrate that Fasn genetic ablation reduces invasive potential in the well‐established prostate‐specific Pten knockout mouse model, which arguably reflects one of the most frequent genetic alterations in human prostate cancer [1]. This evidence concerns the gene PTEN and prostate carcinoma.